ReviewEuropean journal of obstetrics & gynecology and reproductive biology: X2025
Curcumin, a bioactive supplement for premenstrual syndrome and dysmenorrhea: A systematic review of randomised clinical trials.
Review in European journal of obstetrics & gynecology and reproductive biology: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The anti-inflammatory nature of curcumin suggests its potential to modulate the body's inflammatory processes, offering a novel avenue for mitigating heightened inflammatory responses often observed in conditions like PMS and dysmenorrhea. Methods: MEDLINE, Cochrane Central, ScienceDirect, Web of Science, CINAHL, ClinicalTrials.gov, and Google Scholar from their inception to November 12, 2023. The review was conducted according to the Cochrane Handbook for Systematic Reviews of Interventions. The outcomes of interest encompassed evaluating the severity of PMS symptoms and dysmenorrhea, including physical symptoms, behavioral symptoms, mood symptoms. Additionally, the study focused on assessing inflammatory biomarkers, Iron profile and Vitamin D status as other outcomes. Results: Ten randomized controlled trials have evaluated the effectiveness of curcumin in reducing premenstrual syndrome and dysmenorrhea symptoms in women. These studies used various scales such as the Premenstrual Syndrome Screening Tool (PSST) and visual analog scale. Out of ten trials, six of them reported a significant decrease in PMS and dysmenorrhea symptoms. Additionally, six studies evaluated curcumin's association with inflammatory markers, hematological parameters, iron profile, Vitamin D, and sleep patterns. This demonstrated significant association between curcumin and inflammatory markers (nitric oxide metabolites, BDNF, IgE, Il-10, IL-12, hs-CRP), and vitamin D status. Conclusion: The findings of this systematic review suggest that curcumin holds promise in the management of PMS and dysmenorrhea. However, further research is needed to establish optimal dosages and treatment durations, considering potential interactions with iron metabolism. The results encourage the exploration of curcumin as a complementary approach in enhancing the overall well-being of individuals affected by these menstrual conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.